TORII PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,855 JPY | +1.72% |
|
+4.47% | +8.44% |
| Feb. 13 | LIM Advisors Partially Withdraws Shareholder Proposal | CI |
| Feb. 09 | Torii Pharmaceuticals Opposes Shareholder Proposal | CI |
ETFs positioned on Torii Pharmaceutical Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.12% | 15 M€ | +7.34% | ||
| 0.05% | 2 M€ | -.--% | ||
| 0.02% | 7 M€ | -.--% | - | |
| 0.01% | 18 M€ | +16.15% | - | |
| 0.01% | 20,721 M€ | +13.52% | - | |
| 0.01% | 66,066 M€ | +14.68% | - | |
| 0.01% | 144,586 M€ | +14.49% | ||
| 0.00% | 10 M€ | -3.35% | - |
TORII PHARMACEUTICAL CO., LTD. is mainly engaged in the manufacture and sale of pharmaceutical products. The Companyâs main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Companyâs main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.44% | 688M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4551 Stock
- Funds and ETFs Torii Pharmaceutical Co., Ltd.
